C-Rad AB Class B (24C) AI Stock Analysis

Top Page

C-Rad AB Class B

(Frankfurt:24C)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Conservative balance sheetVery low leverage gives C-Rad substantial financial flexibility and limits refinancing risk as it funds operations and growth. A conservative capital structure also reduces dependence on external financing, allowing the company to withstand uneven earnings or cash conversion without excessive balance-sheet strain.

Negative Factors

Contracting revenueA shrinking top line is a fundamental concern because it suggests current demand or deployment activity is not expanding at the pace required to support durable growth. Continued contraction could reduce operating leverage, limit reinvestment capacity, and make future earnings more dependent on cost control.

C-Rad AB Class B (24C) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 71.15M
Dividend Yield: 0.43%
Average Volume (3M): 25
Price to Earnings (P/E): 16.5
Beta (1Y): 0.43
Revenue Growth: -6.15%
EPS Growth: 111.46%
Country: Germany
Employees: 98
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Specialties

C-Rad AB Class B Business Overview & Revenue Model

Company Description

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient po...

C-Rad AB Class B Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:24C against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:SECT.B	79Outperform	SEK 67.51B	105.81	30.26%	0.38%	13.94%	5.70%
SE:ALIF.B	74Outperform	SEK 22.23B	34.66	11.32%	0.82%	1.62%	63.45%
SE:RAY.B	67Neutral	SEK 6.95B	32.66	22.81%	1.97%	1.42%	10.40%
SE:XVIVO	64Neutral	SEK 6.46B	50.12	5.89%	―	17.83%	330.94%
SE:PAX	60Neutral	SEK 1.54B	-303.85	-1.22%	―	34.05%	-144.96%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:24C and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:24C	C-Rad AB Class B	2.00	-0.91	-31.33%
SE:ALIF.B	AddLife AB Class B	182.30	-17.62	-8.81%
SE:PAX	Paxman AB	66.30	-1.10	-1.63%
SE:RAY.B	RaySearch Laboratories AB Class B	202.80	-16.56	-7.55%
SE:XVIVO	Xvivo Perfusion AB	205.00	22.50	12.33%
SE:SECT.B	Sectra AB Class B	346.00	49.17	16.56%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

C-Rad AB Class B AI Stock Analysis